英特集团回应董事长变更

Core Viewpoint - The recent leadership changes at Yingte Group, including the resignation of Chairman Ying Xueqi and the election of Wang Yang as the new chairman, are part of normal personnel adjustments within the company [1][3]. Company Overview - Yingte Group is a large regional pharmaceutical distribution enterprise in China, involved in various sectors including pharmaceuticals, medical devices, new retail, logistics, and traditional Chinese medicine, with a significant sales network in East China, particularly Zhejiang [2]. - The company is controlled by Zhejiang Provincial State-owned Assets Supervision and Administration Commission and has undergone several ownership changes since its establishment in 1950 [2][3]. Leadership Changes - Ying Xueqi has resigned from all positions within Yingte Group, while Wang Yang has been elected as the new chairman, with his term lasting until the current board's term ends [1][3]. - Ying Xueqi has a long tenure with the company, having joined in 1995, while Wang Yang has held various leadership roles within the organization [3][4]. Financial Performance - Yingte Group's revenue has grown significantly, surpassing 300 billion yuan, with annual revenues from 2018 to 2023 reported as follows: 204.92 billion, 246.01 billion, 250.08 billion, 267.31 billion, 306.19 billion, and 320.52 billion yuan [5]. - The company's profitability remains relatively weak, with gross and net profit margins consistently around 6%-6.8% and 1%-1.8% respectively since 2018 [5]. - For the first three quarters of 2024, Yingte Group reported a revenue of 247.77 billion yuan, a year-on-year increase of 3.59%, and a non-recurring net profit of 3.4 billion yuan, up 24.54% year-on-year [5].